Summary
The Food and Drug Administration (FDA) under HHS is forecasting a funding opportunity for studies addressing rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). This is a forecasted opportunity posted on Grants.gov, indicating early-stage planning for research grants or cooperative agreements in this area. No detailed scope, award amounts, or eligibility requirements are available in the current notice beyond the high-level topic area.
